13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

2948 trials found

diseases per page:

Showing 1 to 10 of 2,948 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04880577 (ClinicalTrials.gov)	September 15, 2022	30/4/2021	Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple ...	Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple ...	Multiple Sclerosis, Relapsing-Remitting;Fatigue	Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];Drug: Placebo	Harvard Medical School	Gilead Sciences	Not yet recruiting	18 Years	N/A	All	60	Phase 2	NULL
2	NCT05266469 (ClinicalTrials.gov)	May 1, 2022	23/2/2022	Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the G ...	Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofa ...	Relapsing Multiple Sclerosis	Other: Ofatumumab;Other: Ocrelizumab	Novartis Pharmaceuticals	NULL	Not yet recruiting	18 Years	100 Years	All	240		NULL
3	NCT05090033 (ClinicalTrials.gov)	April 30, 2022	22/9/2021	Characterizing the Use of Ofatumumab in a Real World Setting	Secondary Use of Data Study Characterizing Kesimpta (Ofatumumab) Onboarding and Utilization in RMS P ...	Relapsing Multiple Sclerosis	Other: ofatumumab	Novartis Pharmaceuticals	NULL	Not yet recruiting	18 Years	N/A	All	3500		NULL
4	NCT05285891 (ClinicalTrials.gov)	April 30, 2022	8/3/2022	Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Randomized, Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis (AMS0 ...	Multiple Sclerosis	Biological: Ocrelizumab;Drug: Placebo for Ocrelizumab	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence (ACE)	Not yet recruiting	18 Years	55 Years	All	175	Phase 4	NULL
5	NCT05232825 (ClinicalTrials.gov)	March 31, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investiga ...	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical ...	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: Dex ...	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	65 Years	All	232	Phase 3	United States;Brazil;Canada;Czechia;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine
6	NCT05285904 (ClinicalTrials.gov)	March 30, 2022	8/3/2022	Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study	Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study (KOSMOS)	Multiple Sclerosis	Other: Ofatumumab	Novartis Pharmaceuticals	NULL	Not yet recruiting	18 Years	99 Years	All	149		NULL
7	NCT05265728 (ClinicalTrials.gov)	March 25, 2022	23/2/2022	A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Na ...	A Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Phar ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab	Biogen	NULL	Not yet recruiting	18 Years	65 Years	All	20	Phase 3	NULL
8	EUCTR2021-004791-34-NL (EUCTR)	16/03/2022	15/03/2022	Personalized dosing of ocrelizumab in MS	Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab i ...	Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Ocrevus Product Name: ocrelizumab	VU medical center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	296	Phase 4	Netherlands
9	EUCTR2020-005448-48-CZ (EUCTR)	15/03/2022	05/05/2021	A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical ...	A PHASE III, NON-INFERIORITY, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP, MULTICENTER STUDY TO INVESTIGA ...	Multiple Sclerosis (MS) MedDRA version: 21.1;Level: PT;Classification code 10063401;Term: Primary pr ...	Trade Name: Ocrevus Product Name: ocrelizumab Product Code: RO4964913 INN or Proposed INN: Ocrelizumab O ...	F. Hoffmann-La Roche Ltd	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	232	Phase 3	United States;Czechia;Spain;Ukraine;Turkey;Russian Federation;Italy;France;Czech Republic;Canada;Pol ...
10	NCT05269004 (ClinicalTrials.gov)	March 15, 2022	11/2/2022	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multi ...	A Multicenter, Single-Arm, Open-Label, Extension, Rollover Study To Evaluate The Long-Term Safety An ...	Multiple Sclerosis	Drug: Ocrelizumab	Hoffmann-La Roche	NULL	Not yet recruiting	18 Years	N/A	All	1300	Phase 3	NULL

First Previous1 2 3 4 5…295Next Last